Results 81 to 90 of about 22,921 (213)

Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease-A Comparative Clinical Study. [PDF]

Pharmacy (Basel), 2023
Nain P, Nayak N, Maj MC, Singh RK, Kaur J, Jeong Y, Maity S, Nath R, Hilgers RH, Nauhria S, Nauhria S.   +10 more
europepmc   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Calcium-Based Phosphate Binders and Plasma Oxalate Concentration in Dialysis Patients. [PDF]

J Am Soc Nephrol, 2022
Oka Y, Miyazaki M, Takatsu S, Matsuda H.
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Authors' Reply: Calcium-Based Phosphate Binders and Plasma Oxalate Concentration in Dialysis Patients. [PDF]

J Am Soc Nephrol, 2022
Pfau A, Knauf F.
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Quantifying the Contribution of Nondialytic Factors Affecting Predialysis Serum Phosphate Level When Comparing Hemodiafiltration with Hemodialysis

Toxins
Hyperphosphatemia is a major complication in patients with kidney failure undergoing dialysis and is strongly associated with cardiovascular disease, vascular calcification, and increased mortality.
John T. Daugirdas
doaj   +1 more source

Do we need new phosphate binders in dialysis? [PDF]

Clin Kidney J, 2021
Cozzolino M, Galassi A, Ciceri P.
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Phosphate binders in dialysis: better satisfied than sorry. [PDF]

Clin Kidney J, 2021
Cozzolino M, Galassi A, Ciceri P.
europepmc   +1 more source